Shah Y, Kulm S, Nauseef JT, Chen Z, Elemento O, Kensler KH, Sharaf RN.
2024.
Benchmarking multi-ancestry prostate cancer polygenic risk scores in a real-world cohort.. PLoS Comput Biol. 20(4):e1011990.
Kasi PM, Lee JK, Pasquina LW, Decker B, Borre PVanden, Pavlick DC, Allen JM, Parachoniak C, Quintanilha JCF, Graf RP et al..
2024.
Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.. Clin Cancer Res. 30(4):836-848.
Li S, Wong A, Sun H, Bhatia V, Javier G, Jana S, Wu Q, Montgomery RB, Wright JL, Lam H-M et al..
2024.
A combinatorial genetic strategy for exploring complex genotype-phenotype associations in cancer.. Nat Genet. 56(3):371-376.
Noch EK, Palma L, Yim I, Bullen N, Barnett D, Walsh A, Bhinder B, Benedetti E, Krumsiek J, Gurvitch J et al..
2024.
Cysteine induces mitochondrial reductive stress in glioblastoma through hydrogen peroxide production.. Proc Natl Acad Sci U S A. 121(8):e2317343121.
Beltrán-Visiedo M, Del Valle ASerrano-, Jiménez-Aldúan N, Soler-Agesta R, Naval J, Galluzzi L, Marzo I.
2024.
Cytofluorometric assessment of calreticulin exposure on CD38+ plasma cells from the human bone marrow.. Methods Cell Biol. 189:189-206.
Uemura M, Kikukawa H, Hashimoto Y, Uemura H, Mizokami A, Kato M, Matsushima H, Kosaka T, Nakamura M, Fukasawa S et al..
2024.
Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.. Cancer Med. 13(21):e70029.
Ohara K, Assaad MAl, McNulty SN, Alnajar H, Sboner A, Wilkes DC, He F, Xiang JZhaoying, Mathew S, Elemento O et al..
2024.
Detection of rare and novel gene fusions in patients with diffuse glioma: An institutional retrospective study.. J Neuropathol Exp Neurol.
Klomp JE, J Diehl N, Klomp JA, A Edwards C, Yang R, Morales AJ, Taylor KE, Drizyte-Miller K, Bryant KL, Schaefer A et al..
2024.
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.. Science. 384(6700):eadk0850.